Shiva Toumaj

Dr. Shiva Toumaj

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 April 2025 in Engineering Applications of Artificial Intelligence
Verified
Journal Article
Open access
HWHongyuan Wang
Hongyuan Wang
STShiva Toumaj
Shiva Toumaj
Arash HeidariArash Heidari
Arash Heidari
ASAlireza Souri
Alireza Souri
NJNima Jafari
Nima Jafari
YJYiping Jiang
Yiping Jiang

11 November 2025 in Bioengineering
Verified
Journal Article
Open access
PDF file
MDMuhiddin Dervis
Muhiddin Dervis
AMAhmed Marey
Ahmed Marey
STShiva Toumaj
Shiva Toumaj
RQRuaa Mustafa Qafesha
Ruaa Mustafa Qafesha
DMDoaa Mashaly
Doaa Mashaly
MUMuhammad Umair
Muhammad Umair
Magnetic Particle Imaging (MPI) is a new type of tracer-based imaging that has great spatial and temporal resolution, does not require ionizing radiation, and can see deep into tissues by directly measuring the nonlinear magnetization response of superparamagnetic iron oxide nanoparticles (SPIONs). Unlike Magnetic Resonance Imaging (MRI) or Computed Tomography (CT), MPI has very high contrast and quantitative accuracy, which makes it perfect for use in dynamic cardiovascular applications. This study presents a full picture of the most recent changes in cardiac MPI, such as the physics behind Field-Free Point (FFP) and Field-Free Line (FFL) encoding, new ideas for tracer design, and important steps in the evolution of scanner hardware. We discuss the clinical relevance of cardiac MPI in visualizing myocardial perfusion, quantifying blood flow, and guiding real-time interventions. A hybrid imaging workflow, which improves anatomical detail and functional assessment, is utilized to explore the integration of MPI with complementary modalities, particularly MRI. By consolidating recent preclinical breakthroughs and highlighting the roadmap toward human-scale implementation, this article underscores the transformative potential of MPI in cardiac diagnostics and image-guided therapy.

29 May 2026 in Bioengineering
Verified
Journal Article
Open access
PDF file
STShiva Toumaj
Shiva Toumaj
AAAhmed Afifi
Ahmed Afifi
MDMuhiddin Dervis
Muhiddin Dervis
DMDoaa Mashaly
Doaa Mashaly
AAAbdallah Abudraz
Abdallah Abudraz
MUMuhammad Umair
Muhammad Umair
Background: Magnetic particle imaging (MPI) is an emerging, tracer-based modality that directly detects superparamagnetic iron oxide nanoparticles (SPIONs) with exceptional sensitivity, quantitative signal behavior, and full immunity to air–tissue susceptibility artifacts. These features make MPI particularly well-suited for pulmonary imaging, where traditional techniques such as computed tomography (CT), magnetic resonance imaging (MRI), and nuclear medicine-based ventilation/perfusion (V/Q) imaging are limited by radiation exposure, low contrast, and motion-related signal degradation. Objective: This review synthesizes the current state of MPI for lung imaging, with emphasis on its physical principles, tracer development, preclinical applications, and its potential role in assessing pulmonary perfusion, vascular integrity, inflammation, and therapeutic responses. Methods: A systematic evaluation of preclinical studies was performed across three major application domains: pulmonary perfusion mapping, cell tracking and therapeutic monitoring, and vascular injury and permeability assessment. Study designs, SPION formulations, MPI acquisition strategies, and validation methods, including histopathology, biodistribution, broncho-alveolar lavage fluid (BALF) analysis, and Evans Blue assays, were examined to characterize methodological consistency and imaging performance. Results: MPI consistently demonstrated high-contrast, quantitative visualization of pulmonary blood flow, endothelial barrier disruption, inflammatory signaling, and transplanted or inhaled cell populations. Tracer engineering played a critical role: macroaggregated albumin superparamagnetic iron oxide nanoparticles (MAA-SPIONs) enabled capillary-level perfusion mapping, LS-008 improved temporal resolution and vascular delineation, Synomag/Synomag-D allowed quantification of vascular leakage in acute and chronic lung injury, and vascular cell adhesion molecule-1 (VCAM-1)-targeted probes provided molecular-level assessment of inflammation. Hybrid MPI-CT and MPI-MRI approaches further enhanced anatomic localization and enabled accurate pulmonary blood volume (PBV) estimation. Across studies, MPI measurements showed strong agreement with established biological assays and remained free of the artifacts that limit CT and MRI in the lung. Conclusions: Preclinical evidence demonstrates that MPI is a robust, radiation-free, and quantitatively precise modality for functional and molecular lung imaging. Its ability to map perfusion, track therapeutic agents, and noninvasively quantify vascular permeability positions MPI as a promising future alternative or complement to CT, MRI, and nuclear medicine for pulmonary assessment. Continued tracer optimization, system scaling, and clinical validation are key steps toward translating MPI into routine clinical use.

27 June 2023 in Journal of Parathyroid Disease
Verified
Journal Article
Open access
PDF file
STShiva Toumaj
Shiva Toumaj
Brown tumor in hyperparathyroidism; a new look at an old problem

1 January 2023 in Journal of Renal Endocrinology
Verified
Journal Article
Open access
PDF file
ARAli Rastegar-Kashkouli
Ali Rastegar-Kashkouli
MJMohsen Jafari
Mohsen Jafari
PYPourya Yousefi
Pourya Yousefi
Shahrzad AlimohammadiShahrzad Alimohammadi
Shahrzad Alimohammadi
HMHoda Miranzadeh Mahabadi
Hoda Miranzadeh Mahabadi
Hamid NasriHamid Nasri
Hamid Nasri
Each year, a considerable number of individuals are diagnosed with potentially life-threatening renal failure, encompassing acute kidney injury (AKI) and chronic kidney disease (CKD). New natural herbal compounds, whether used in isolation or combined with medical treatments and an appropriate regime, have been suggested for the management of renal failure. The etiology of AKI remains uncertain; nevertheless, several factors have been proposed as potential causative agents that can lead to renal failure, including renal ischemia-reperfusion injury (IRI), nephrotoxicity, sepsis, administration of radiocontrast agents, and exposure to heavy metal ions. Several commonly utilized herbs with anti-diabetic and antihypertensive properties, known for their antioxidant, anti-inflammatory, and vasorelaxant effects, have been recognized as efficacious therapeutic agents in the management of CKD. The management of renal failure typically involves treating the underlying diseases, such as IRI, sepsis, and diabetes. However, if addressing the root cause is not possible, the focus shifts to managing complications like hypertension and proteinuria.

3 June 2023 in Journal of Nephropharmacology
Verified
Journal Article
Open access
PDF file
STShiva Toumaj
Shiva Toumaj
Shahrzad AlimohammadiShahrzad Alimohammadi
Shahrzad Alimohammadi
MGMaryam Ghasemi
Maryam Ghasemi
SSShokouh Shayanpour
Shokouh Shayanpour
Immunoglobulin A nephropathy is the most common kind of primary glomerulonephritis worldwide and one of the main causes of renal failure. Systemic corticosteroid therapy may protect against renal deterioration in IgA nephropathy; however, it is not often advised for long-term treatment due to possible side effects. Recent studies present promising results of the new targeted-release formulation of budesonide that delivers the drug to the distal ileum to reduce side effects for patients with IgA nephropathy. In this paper, we highlighted the potential benefits of budesonide as a treatment option for IgA nephropathy and the need for additional studies to confirm its effectiveness. The lack of alternative treatments to prevent renal deterioration without other systemic side effects motivated us to gather relevant information to fill this gap. In this brief overview, we have reviewed some of the most recently published studies regarding how budesonide protects against IgA nephropathy. Studies reveal that budesonide might significantly decrease proteinuria, hematuria, and creatinine level while maintaining normal renal function. Though, a limited number of trials have been established to date, and further investigations are needed to confirm the benefit of the new targeted-release budesonide in treating IgA nephropathy.